BTG3 and scleroderma: These findings reinforce the diagnostic value of N-ANA in systemic sclerosis and overlap syndromes, where anti-Scl70 and anti-Pm-Scl100 serve as serological markers for diffuse cutaneous systemic sclerosis and scleroderma-polymyositis overlap, respectively [13].